To assess the impact of study site and the year of publication on the results of trials assessing the effects of naltrexone for the treatment of alcohol dependence.
Results of the review
Nineteen randomised controlled trials were included (n=2,691: 1,454 received naltrexone and 1,237 received placebo).
Twelve studies were single-site and seven were multi-site.
The average effect size for the percentage of drinking days was significantly greater than zero with naltrexone for both single site studies (d=0.33, 95% CI: 0.10, 0.56) and multicentre studies (d=0.17, 95% CI: 0.03, 0.36). There was no significant difference in the effect sizes between single-site studies and multicentre studies. The effect of the year of publication showed a non significant negative trend, with earlier studies showing larger effect sizes. The inclusion of both study type and year of publication as predictors of effect size reduced the magnitude of both effects.
The effect size estimates for the percentage of participants who relapsed to heavy drinking was significantly greater than zero with naltrexone for both single-site studies (d=0.41, 95% CI: 0.25, 0.55) and multicentre studies (d=0.17, 95% CI: 0.04, 0.29). The effect size estimates from multicentre studies were significantly smaller than the average effect size for single-site studies. The effect of the year of publication was also significant, with smaller effect sizes in more recent studies. The inclusion of both the type of study and the year of publication resulted in neither factor being a significant predictor of effect size.
Authors' conclusions
The smaller effect sizes seen in multicentre studies may reflect random error due to differences among the sites. However, since more recent publications also had smaller effect sizes, and multi-centre studies tended to be more recent than single-site studies, it was not possible to separate out the influence on effect size of study type and year of publication.
CRD commentary
The review question was clearly defined in terms of the interventions, outcomes and study designs. Only one database was searched for potentially relevant studies, and it was unclear whether any language restrictions were applied. No efforts were made to locate ongoing or unpublished studies, which may introduce publication bias into the review. It was unclear how studies were selected for the review and how the data were extracted, thus it is unknown whether any efforts were made to minimise reviewer bias and errors in these processes. The quality of the primary studies was not assessed, so the quality of the evidence base that underpins the review cannot be judged. In addition, as no details of the primary studies were presented, it is unclear whether combining the studies in a meta-analysis was appropriate, given the fact that there might have been clinically relevant differences between the participants included in the trials. The lack of a description of the review methods and the lack of a quality assessment make it difficult to comment on the reliability of the evidence underpinning the authors' conclusions.
